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Introduction {#sec1}
============

Hematopoiesis is a hierarchy with hematopoietic stem cells (HSCs) at the apex ([@bib24]). Tasked with self-renewal to replenish the stem cell pool, and differentiation to maintain blood production, HSCs must possess functional integrity for the lifetime of an individual. Somatic mutations acquired during aging can adversely affect this balance, resulting in hematologic disorders. Two alleles recurrently mutated in blood diseases are the epigenetic regulators DNA methyltransferase 3 alpha (*DNMT3A*) and tet methylcytosine dioxygenase 2 (*TET2*) ([@bib4]). Tumor evolution analysis suggests that these mutations are established in HSCs of these patients ([@bib1], [@bib26]). In addition, variants in *DNMT3A* and *TET2* are the most prevalent events associated with clonal hematopoiesis (CH), where pathogenic mutations are found in the blood of elderly people lacking overt disease ([@bib2], [@bib11], [@bib13], [@bib29]). These data suggest that *DNMT3A* and *TET2* mutations confer fitness advantages to HSCs.

Despite similarities in disease phenotypes, DNMT3A and TET2 possess antagonistic biochemical activity. DNMT3A catalyzes addition of methyl groups to DNA forming 5-methylcytosine ([@bib23]), while TET2 promotes DNA demethylation by oxidizing the methyl group to 5-hydroxymethylcytosine ([@bib16]). Each mutation alters the DNA methylome in a predictable manner. In patients with acute myeloid leukemia (AML), *DNMT3A* mutations yield mild hypomethylation of the genome ([@bib27]), while *TET2* mutations result in hypermethylation ([@bib10]). However, loss of function of either enzyme in murine hematopoietic progenitors paradoxically results in similar altered function, including a competitive advantage of mutant cells ([@bib6], [@bib7], [@bib8], [@bib20], [@bib22]). The mechanisms contributing to increased fitness of *DNMT3A*- and *TET2*-mutant HSCs remain largely undefined. The goal of this study was to directly compare loss-of-function effects of *Dnmt3a* and *Tet2* at the HSC level through functional assays and molecular profiling.

Results {#sec2}
=======

Loss of Dnmt3a and Tet2 Enhances Self-Renewal in HSCs to Different Degrees {#sec2.1}
--------------------------------------------------------------------------

To directly compare the effects of *Dnmt3a* and *Tet2* loss of function on HSC fate, we performed parallel competitive HSC transplants. Floxed *Dnmt3a* ([@bib15]) or *Tet2* ([@bib22]) mice were crossed with *Mx1-Cre* ([@bib18]). Treatment with polyinosinic:polycytidylic acid (pI:pC) created conditional knockout mice (*Dnmt3a*-KO^Mx1^ and *Tet2*-KO^Mx1^). *Mx1-Cre*;*Dnmt3a*^+/+^;*Tet2*^+/+^ mice (Control^Mx1^) were similarly treated with pI:pC. Eight weeks after pI:pC, 200 HSCs (Lineage^−^ c-Kit^+^ Sca-1^+^ CD48^−^ CD150^+^) were transplanted with 2.5 × 10^5^ whole bone marrow (WBM) competitor into wild-type mice ([Figure 1](#fig1){ref-type="fig"}A). No differences were noted in HSC abundance in donor mice ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Blood analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}B) revealed significantly higher contribution to all major hematopoietic lineages from *Tet2*-KO^Mx1^ HSCs compared with control and *Dnmt3a*-KO^Mx1^ HSCs in primary recipients ([Figure 1](#fig1){ref-type="fig"}B). In the bone marrow (BM) 18 weeks post-transplant ([Figure S1](#mmc1){ref-type="supplementary-material"}C), the abundance of both mutant HSC populations was 2-fold higher than Control^Mx1^ HSCs ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Loss of Dnmt3a and Tet2 Enhance Self-Renewal in HSCs to Different Degrees(A) HSC serial transplantation schematic. In descending column order---contribution of 200 Control^Mx1^, *Dnmt3a*-KO^Mx1^ (3aKO), and *Tet2*-KO^Mx1^ (T2KO) HSCs to peripheral blood, lineage chimerism, HSC frequency, and HSC number in (B) primary (CNT n = 28; 3aKO n = 24; T2KO n = 22), (C) secondary (CNT n = 27; 3aKO n = 19; T2KO n = 21), and (D) tertiary (CNT n = 33; 3aKO n = 23; T2KO n = 19) transplants. (E) Self-renewal and (F) differentiation quotients of indicated HSC genotypes after each transplant. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.001. Mean ± SEM is shown.

Loss of *Dnmt3a* confers HSCs with unlimited self-renewal ([@bib14]). To test if *Tet2*-KO^Mx1^ HSCs possess the same ability, serial competitive HSC transplantation was performed. Two hundred donor-derived (CD45.2^+^) HSCs were purified from primary recipients and transferred to secondary recipients with 2.5 × 10^5^ fresh (CD45.1^+^) WBM competitor. *Tet2*-KO^Mx1^ HSCs maintained significantly higher blood production ([Figure 1](#fig1){ref-type="fig"}C), and donor-derived HSCs were increased elevated in recipients of both mutant HSC genotypes ([Figure 1](#fig1){ref-type="fig"}C). When examining other progenitor populations ([Figure S1](#mmc1){ref-type="supplementary-material"}D), donor-derived multipotent progenitor 1 (\[MPP1\] Lineage^−^ c-Kit^+^ Sca-1^+^ CD48^−^ CD150^−^) and MPP3 (Lineage^−^ c-Kit^+^ Sca-1^+^ CD48^+^ CD150^−^) populations were significantly increased in *Tet2*-KO^Mx1^ secondary recipients ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). However, after tertiary transplant, *Tet2*-KO^Mx1^ HSCs surprisingly exhausted to similar levels as control HSCs ([Figure 1](#fig1){ref-type="fig"}D).

The ratio of donor-derived HSCs to 200 input HSCs ("self-renewal quotient") quantifies the average self-renewal of a single test HSC ([@bib7]). *Dnmt3a*-KO^Mx1^ and *Tet2*-KO^Mx1^ HSCs both possess greater self-renewal on a per-HSC basis than control HSCs after primary transplant ([Figure 1](#fig1){ref-type="fig"}E). But the self-renewal quotient of *Tet2*-KO^Mx1^ HSCs overlaps with Control^Mx1^ HSCs at the end of tertiary transplant, in contrast to *Dnmt3a*-KO^Mx1^ HSCs ([Figure 1](#fig1){ref-type="fig"}E). When examining the differentiation capacities of HSCs (16-week WBC count multiplied by percentage of donor-derived peripheral blood cells at 16 weeks divided by the total number of test HSCs, or the "differentiation quotient") both *Dnmt3a*-KO^Mx1^ and *Tet2*-KO^Mx1^ HSCs display a reduced differentiation output on a per-HSC basis ([Figure 1](#fig1){ref-type="fig"}F).

Tet2 and Dnmt3a Loss of Function Divergently Influence Rate of Transformation from Same Co-operating Mutation {#sec2.2}
-------------------------------------------------------------------------------------------------------------

To compare functional contribution of *Dnmt3a* and *Tet2* loss of function with leukemogenesis, we crossed *Flt3* internal tandem duplication (*Flt3*^ITD^) knockin mice ([@bib19]) to *Vav-Cre*;*Dnmt3a*^fl/fl^ or *Vav-Cre*;*Tet2*^fl/fl^ mice (*Dnmt3a*-KO^Vav^ and *Tet2*-KO^Vav^). *Flt3*^ITD^ mutation significantly decreased time to morbidity in both genetic backgrounds, but the magnitude varied. Median survival in a *Tet2*-deficient background decreased ∼5.2-fold with expression of *Flt3*^ITD^, whereas survival of *Dnmt3a*-KO^Vav^ mice only decreased ∼1.5-fold ([Figure 2](#fig2){ref-type="fig"}A). Both *Dnmt3a*-KO^Vav^*Flt3*^ITD/+^ and *Tet2*-KO^Vav^*Flt3*^ITD/+^ mice presented with leukocytosis ([Figure 2](#fig2){ref-type="fig"}B), anemia, splenomegaly ([Figure S2](#mmc1){ref-type="supplementary-material"}A), and AML ([Figure 2](#fig2){ref-type="fig"}C). A proportion of *Dnmt3a*-KO^Vav^*Flt3*^ITD/+^ mice developed mixed phenotype acute leukemia, consistent with the role of Dnmt3a as a T cell leukemia tumor suppressor ([@bib17]). *Dnmt3a*-KO^Vav^ mice without *Flt3*^ITD^ predominantly developed BM failure resembling myelodysplastic syndromes, whereas most *Tet2*-KO^Vav^ mice developed myeloproliferative disorders or myeloproliferative neoplasms.Figure 2Tet2 and Dnmt3a Loss of Function Divergently Influence Rate of Transformation from Same Co-operating Mutation(A) Kaplan-Meier plot comparing time to morbidity between Control^Vav^ (n = 30), *Flt3*^ITD^ (n = 20), *Dnmt3a*-KO^Vav^ (n = 15), *Tet2*-KO^Vav^ (n = 11), *Dnmt3a*-KO^Vav^*Flt3*^ITD^ (n = 16), and *Tet2*-KO^Vav^*Flt3*^ITD^ (n = 12) mice.(B) White blood cell count of day 600 Control^Vav^ and moribund mice of indicated genotypes.(C) Pathological diagnosis of moribund mice.(D) Representative flow cytometry plots of moribund mice demonstrating expansion of MPP3 (red box) and depletion of HSCs (purple box) in *Flt3*^ITD^ genotypes.(E) Frequency and number of HSCs and MPP3 in moribund mice.(F--J) (F) Frequency and number of HSCs and MPP3 in 8-week-old Control^Vav^ (n = 18), *Flt3*^ITD^ (n = 14), *Dnmt3a*-KO^Vav^ (n = 18), *Dnmt3a*-KO^Vav^*Flt3*^ITD^ (n = 10), *Tet2*-KO^Vav^ (n = 15), and *Tet2*-KO^Vav^*Flt3*^ITD^ (n = 9) mice. Pathological analysis of young adult mice showing (G) WBC counts, (H) peripheral blood myeloid cells, (I) spleen weights, and (J) spleen myeloid cells. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.001. Mean ± SEM is shown.

Analysis of BM progenitors in moribund mice revealed significant expansion of the MPP3 population in *Flt3*^ITD^ mice ([Figure 2](#fig2){ref-type="fig"}D). *Flt3*^ITD^ depleted HSCs such that even the enhanced self-renewal of *Dnmt3a*-KO^Vav^ could not rescue ([Figure 2](#fig2){ref-type="fig"}E). The synergism between *Tet2* loss of function and *Flt3*^ITD^ alleles in promoting MPP3 expansion was already detectable in the BM of young adult mice lacking overt disease ([Figure 2](#fig2){ref-type="fig"}F), associated with leukocytosis ([Figure 2](#fig2){ref-type="fig"}G), myeloproliferation ([Figures 2](#fig2){ref-type="fig"}H and [S2](#mmc1){ref-type="supplementary-material"}B), splenomegaly ([Figures 2](#fig2){ref-type="fig"}I and 2J), and lymphoid depletion ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Even though *FLT3*^ITD^ mutations co-occur in patients with AML with both *DNMT3A* and *TET2* mutations ([@bib4]), the synergism in *Tet2*-KO^Vav^*Flt3*^ITD/+^ mice show that founding mutations in *Dnmt3a* and *Tet2* have disparate sensitivities to the same co-operating mutation.

Tet2 Mutation Does Not Impart Ectopic Self-Renewal to Hematopoietic Progenitors, but Loss of Dnmt3a Confers Phenotypic Plasticity {#sec2.3}
---------------------------------------------------------------------------------------------------------------------------------

Expansion of the MPP3 population in moribund *Flt3*^ITD^ mice implicated this BM compartment as the disease-initiating cell population. To test this, 250 MPP3 from young mice were transplanted with 2.5 × 10^5^ wild-type WBM competitor cells. Regardless of genotype, donor-derived cells were barely detectable in the blood ([Figure S3](#mmc1){ref-type="supplementary-material"}A) and failed to engraft the BM and generate disease (data not shown). This demonstrates that neither loss of *Dnmt3a* nor *Tet2*, alone or combined with *Flt3*^ITD^, imparts self-renewal properties to normally non-self-renewing progenitors.

Transplantation of Control^Vav^, *Tet2*-KO^Vav^, and *Dnmt3a*-KO^Vav^ WBM against equal numbers of wild-type BM confirmed the competitive advantage of unfractionated *Tet2*-KO^Vav^ BM ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). But as *Tet2*-KO^Mx1^ HSC self-renewal was eventually exhausted ([Figure 1](#fig1){ref-type="fig"}D), this suggested that a non-HSC progenitor population may contribute to the observed myeloid dominance from *Tet2*-mutant BM. We performed competitive transplant of 200 MPP1 ([Figure 3](#fig3){ref-type="fig"}A). Peripheral blood analysis revealed long-term tri-lineage engraftment among recipients of both *Dnmt3a*-KO^Vav^ and *Tet2*-KO^Vav^ MPP1 ([Figure 3](#fig3){ref-type="fig"}B), whereas all recipients of Control^Vav^ MPP1 had \<1% donor-derived myeloid cells ([@bib5]). From BM analysis ([Figure 3](#fig3){ref-type="fig"}C), *Tet2*-KO^Vav^ MPP1 failed to self-renew but *Dnmt3a*-KO^Vav^ MPP1 reconstituted the BM MPP1 compartment ([Figure 3](#fig3){ref-type="fig"}D). Surprisingly, we also observed donor-derived HSCs in all *Dnmt3a*-KO^Vav^ MPP1 recipients ([Figures 3](#fig3){ref-type="fig"}C and 3D). Loss of *Dnmt3a* may bestow epigenetic plasticity between the HSC and MPP1 compartments, reinforcing the importance of Dnmt3a in maintenance of hematopoietic cell type identity.Figure 3Tet2 Mutation Does Not Impart Ectopic Self-Renewal to Hematopoietic Progenitors, but Skews Myeloid Differentiation of Committed Progenitor Cells(A) Donor-derived peripheral blood cells and 16-week lineage chimerism in recipients of 200 MPP1 from Control^Vav^ (n = 8), *Dnmt3a*-KO^Vav^ (n = 7), and *Tet2*-KO^Vav^ (n = 5) mice.(B) Frequency of MPP1-transplanted mice with \>1% donor-derived engraftment in myeloid, B cell, and T cell lineages.(C) Representative plots showing donor-derived MPP1 and HSCs in recipients of *Dnmt3a*-KO^Vav^ MPP1.(D) Frequency and chimerism of donor-derived HSCs and MPP1 in recipients of 200 MPP1.(E) Representative immunophenotyping of *in vitro* differentiated progenitor cells.(F) Immunophenotypic populations produced via *in vitro* differentiation of progenitor cells from Control^Vav^ and *Tet2*-KO^Vav^ mice (n = 4 per population of each genotype). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.001. Mean ± SEM is shown.

Loss of Tet2 Skews Myeloid Differentiation of Committed Progenitor Cells {#sec2.4}
------------------------------------------------------------------------

As increased myeloid output from *Tet2*-deficient HSCs could not be attributed to differences in self-renewal, proliferation ([Figure S3](#mmc1){ref-type="supplementary-material"}D), or apoptosis ([Figure S3](#mmc1){ref-type="supplementary-material"}E), we hypothesized that epigenetic dysfunction may skew myeloid differentiation from hematopoietic progenitors. To quantify this, *in vitro* assays were performed with purified HSCs, MPP1, and MPP3. In methylcellulose, all genotypes initially had the same number of colonies ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Both mutant alleles sustained some colony-forming potential in MPP1 and MPP3 in serial plating. A third passage distinguished *Dnmt3a*-KO^Vav^ HSCs with a significant increase in colony number ([Figure S3](#mmc1){ref-type="supplementary-material"}F). The lack of serial replating of *Tet2*-KO^Vav^ MPP3 *in vitro* was consistent with engraftment failure *in vivo*.

Progenitors were then cultured with hematopoietic cytokines in OP9 stroma-coated plates. After 2 weeks, analysis with myeloid markers Gr-1 and CD11b (Mac-1) showed clear differences from *Tet2*-KO^Vav^ progenitors. A Gr-1^hi^ population was lacking while Gr-1^mid^ and Gr-1^lo^ populations were more prevalent ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Further immunophenotyping ([Figure 3](#fig3){ref-type="fig"}E) revealed a disproportionate production of myeloid cells. Loss of *Tet2* increased dendritic cell and macrophage production from MPP1 and MPP3 at the expense of neutrophils ([Figure 3](#fig3){ref-type="fig"}F). This suggests that the primary function of *Tet2* mutations in hematopoietic progenitors is not to increase self-renewal, but rather skew myeloid output.

Dnmt3a and Tet2 Loss of Function Alter Hematopoietic Progenitor Function through Distinct Molecular Mechanisms {#sec2.5}
--------------------------------------------------------------------------------------------------------------

Transcriptional profiling was performed to elucidate mechanisms underlying the functional differences between HSCs over serial transplantation. Unfortunately, the diminution of Control^Mx1^ and *Tet2*-KO^Mx1^ HSCs at later transplant stages permitted only two replicates ([Table S1](#mmc2){ref-type="supplementary-material"}). As a supplement, HSCs were purified from Control^Vav^, *Dnmt3a*-KO^Vav^, and *Tet2*-KO^Vav^ adult mice ([Table S2](#mmc3){ref-type="supplementary-material"}). The gene expression profiles of Control^Vav^ and *Dnmt3a*-KO^Vav^ HSCs were remarkably similar ([Figure S4](#mmc1){ref-type="supplementary-material"}A), despite their functional differences. *Tet2*-KO^Vav^ HSCs showed a larger dysregulated expression signature ([Figure 4](#fig4){ref-type="fig"}A). Of the 24 genes downregulated in *Dnmt3a*-KO^Vav^ HSCs, 11 also showed significant repression in *Tet2*-KO^Vav^ HSCs ([Figure 4](#fig4){ref-type="fig"}B). Genes, such as *Mki67* and *Hmgb2* also showed consistent downregulation in the mutant HSCs across serial transplant ([Figure S4](#mmc1){ref-type="supplementary-material"}B) and may contribute to the differentiation block. A total of 62 out of 288 (21.5%) genes upregulated in *Dnmt3a*-KO^Vav^ HSCs were shared with *Tet2*-KO^Vav^ HSCs, including *jun* and *Fos*, which form the AP-1 transcription factor complex important in HSC stress response ([@bib21]). Transcriptional analysis was also performed on Control^Vav^ and *Tet2*-KO^Vav^ MPP3 from young adult mice to understand the myeloid lineage skewing arising from loss of *Tet2*. Although there were fewer differentially expressed genes (DEGs) than the HSC comparison of the same genotypes ([Figure 4](#fig4){ref-type="fig"}C), gene set enrichment analysis revealed significantly dysregulated gene sets ([Figure 4](#fig4){ref-type="fig"}D). The major difference was diminished nuclear factor κB signaling in *Tet2*-KO^Vav^ MPP3 ([Figure 4](#fig4){ref-type="fig"}E).Figure 4Dnmt3a and Tet2 Loss of Function Alter Hematopoietic Progenitor Function through Distinct Molecular Mechanisms(A) Principal-component analysis plot of gene expression in Control^Vav^ HSCs (n = 3) and MPP3 (n = 4), *Dnmt3a*-KO^Vav^ HSCs (n = 3), and *Tet2*-KO^Vav^ HSCs (n = 4) and MPP3 (n = 4).(B) Venn diagrams displaying DEG overlap in *Dnmt3a*-KO^Vav^ and *Tet2*-KO^Vav^ HSCs compared with Control^Vav^ HSCs.(C) Heatmaps displaying DEGs (p \< 0.05, fold-change \>1 or \<−1) between Control^Vav^ and *Tet2*-KO^Vav^ HSCs and MPP3.(D) Gene set enrichment analysis showing differentially regulated pathways between Control^Vav^ and *Tet2*-KO^Vav^ MPP3.(E) Gene score enrichment plot of "Hallmark TNFα Signaling via NFkB" gene set in *Tet2*-KO^Vav^ MPP3.(F) ATAC-seq heatmaps from Control^Vav^, *Dnmt3a*-KO^Vav^, and *Tet2*-KO^Vav^ mice. Signals displayed are peaks 1 kb up- and downstream of transcription start sites of protein coding genes.(G) Multi-dimensional scaling plot with distances approximating the largest log~2~ fold-changes in the top 500 peaks between ATAC-seq samples.

ATAC sequencing (ATAC-seq) was performed to examine chromatin accessibility in HSCs, MPP1, and MPP3. The most striking difference was global reduction of open chromatin in *Tet2*-KO^Vav^ HSCs and MPP1 ([Figure 4](#fig4){ref-type="fig"}F), consistent with the function of Tet2 in promoting DNA demethylation at enhancers ([@bib25], [@bib28]). However, *Tet2*-KO^Vav^ MPP3 recovered chromatin accessibility above Control^Vav^ levels, including addition of new peaks at 800 hematopoietic enhancers and 1,232 promoters enriched for myeloid function ([Figure S4](#mmc1){ref-type="supplementary-material"}C). The chromatin landscape of Control^Vav^ and *Dnmt3a*-KO^Vav^ progenitors revealed fewer differences. A multi-dimensional scaling analysis showed the *Dnmt3a*-KO^Vav^ MPP1 cluster closer to HSCs than Control^Vav^ MPP1 ([Figure 4](#fig4){ref-type="fig"}G), supporting the notion of a reduced epigenetic barrier between these cell types in the absence of Dnmt3a. Moreover, areas with reduced chromatin accessibility in *Dnmt3a*-KO^Vav^ MPP1 ([Table S3](#mmc4){ref-type="supplementary-material"}) involved genes involved in hematopoietic lineage specification, such as *Fli1* and *Izkf1*, which may contribute to the differentiation block.

Discussion {#sec3}
==========

Somatic mutations in *DNMT3A* and *TET2* comprise approximately 70% of all variants in age-related CH. The persistence of these mutations ([@bib30]) coupled with their recurrence in blood malignancies of diverse lineages suggests a stem cell origin. Mouse model studies suggest a similar increase in HSC self-renewal after inactivation of both genes. Previous studies demonstrate a competitive advantage for *Tet2*-deficient cells in BM transplantation assays ([@bib20], [@bib22]). Although this is assumed to be due to enhanced HSC self-renewal, these experiments have been performed with WBM or less pure populations of progenitors. Our results using highly purified HSCs show that *Tet2* loss of function modestly increased self-renewal on a per-HSC basis during early passages of transplantation, but this effect was transient and *Tet2*-deficient HSCs exhausted to comparable levels as control HSCs after tertiary transplant. This is in stark contrast to *Dnmt3a*-deficient HSCs which show no signs of self-renewal diminution. Moreover, by transplanting defined numbers of HSCs, our quantification shows that, on a per-cell basis, *Tet2*-mutant HSCs show a similar differentiation deficit as *Dnmt3a*-mutant HSCs. This was not anticipated given the high peripheral blood chimerism observed from transplantation of *Tet2*-null WBM, particularly in the myeloid lineage. Rather, our data suggest that increased myeloid output results from skewed differentiation in progenitors lacking *Tet2*. More open chromatin at enhancers of pro-myeloid differentiation genes in *Tet2*-KO^Vav^ MPP3 may contribute to this phenotype.

Our data are instructive for how these mutations are propagated in humans with chromatin immunoprecipitation. *DNMT3A* mutations are highly specific for the HSC compartment, with the increase in self-renewal potential allowing these mutations to be efficiently propagated in humans with age. The fact that the mutations do not cause massive transcriptional changes still allows these mutant HSCs to function as effective stem cells, but with greater self-renewal to withstand external stresses that would normally force HSC depletion. Although *Tet2* loss of function does not induce ectopic self-renewal in either normal or malignant progenitor cells, this mutation alters the myeloid output of progenitors and potentially sensitizes them to secondary mutations that further drive proliferation. This aligns with evidence in humans showing that these mutations do not have equal potential. Analysis of individuals with CH shows *DNMT3A* mutations can be found in all blood lineages, whereas *TET2* mutations are often absent from T cells ([@bib3]), supportive of differential effects on progenitor lineage differentiation. Our data suggest a model for *TET2*-mutant CH whereby the mutation is acquired in HSCs, but the functional effects of myeloproliferation are realized by more downstream progenitors.

Experimental Procedures {#sec4}
=======================

Detailed methods are provided in [Supplemental Information](#appsec1).

Mice and Transplantation {#sec4.1}
------------------------

The Institutional Animal Care and Use Committee at Washington University approved all animal procedures. All mice were C57Bl/6 background. *Dnmt3a*^fl/fl^ ([@bib15]) and *Tet2*^fl/fl^ ([@bib22]) mice were crossed to *Flt3*^ITD^ ([@bib19]), *Vav-Cre* ([@bib12]), and *Mx1-Cre* ([@bib18]) strains. To induce *Mx1-Cre*, six doses (300 μg) of polyinosinic:polycytidylic acid (pI:pC; Sigma, no. p1530) were administered every 48 h via intraperitoneal injection to 8-week-old mice. Mice were allowed to recover for 6 weeks after the last pI:pC injection before sacrifice for HSC purification. Transplant recipients (C57Bl/6 CD45.1, The Jackson Laboratory strain no. 002014), received a split dose of irradiation (10.5 Gy) ∼4 h apart. Cells were transplanted via retro-orbital injection.

RNA-Seq Data, Quality Control, and Analysis {#sec4.2}
-------------------------------------------

Reads were aligned with STAR v.2.5.4b with Gencode release M20 (GRCm38.p6) genome assembly. Unambiguous read counts were calculated by HTSEQ-count. Data were imported into Noiseq v.2.28.0 for differential gene expression analysis with TMM normalization and batch correction. RNA-seq data are available under GEO [GSE139911](ncbi-geo:GSE139911){#intref0010}.

ATAC-Seq {#sec4.3}
--------

Open chromatin was profiled via the Omni-ATAC method ([@bib9]). Reads were aligned to mm10 with BWA mem v.0.7.17. Duplicates were removed with Picard tools MarkDuplicates v.2.0.1 and bams were processed with snakePipes v.1.3.1. Differential chromatin accessibility was assessed using Rsubread v.1.34.7 and EdgeR v.3.26.8. Peaks were intersected with enhancers using bedtools v.2.25.0. Bigwig tracks and heatmaps were created via deepTools2 v.3.3.1. ATAC-seq data are available under GEO [GSE139911](ncbi-geo:GSE139911){#intref0015}.

Statistics {#sec4.4}
----------

Student's t test, and one- and two-way ANOVA were used for statistical comparisons where appropriate. Kruskal-Wallis test was used for non-normal data. Survival curves were analyzed using a Mantel-Cox log rank test. Significance is indicated using the following convention: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. All graphs represent mean ± SEM.
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